Clinical Trials Logo

Non-infectious Uveitis clinical trials

View clinical trials related to Non-infectious Uveitis.

Filter by:

NCT ID: NCT06258915 Not yet recruiting - Clinical trials for Non Infectious Uveitis

Treatment FOr Corticosteroid Dependent UveitiS

FOCUS
Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

FOCUS is the first prospective randomized study comparing standard of care (mycophenolate mofetil) to adalimumab in recently active non infectious uveitis (NIU) with steroid dependency. There is no firm evidence or randomized trials that compared classical immunosuppressive compounds to biological agents; or identified the best treatment in this condition. The burden of NIU has been reduced with the use of immunosuppressive agents and biologics, raising the question of which of these compounds should be preferentially used in recently active NIU with steroid dependency.

NCT ID: NCT05928754 Not yet recruiting - Clinical trials for Non-infectious Uveitis

Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS

CHRONOS
Start date: September 2023
Phase: N/A
Study type: Interventional

prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and constitution of biological collection.

NCT ID: NCT04207983 Completed - Clinical trials for Non-infectious Uveitis

A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU)

ELECTRO
Start date: February 3, 2020
Phase: Phase 2
Study type: Interventional

The objective of the study is to evaluate the efficacy and safety of two different treatment regimens of EYS606.

NCT ID: NCT04105452 Not yet recruiting - Clinical trials for Non-infectious Uveitis

Study to Evaluate PL8177 in Subjects With Non Infectious Uveitis (NIU)

Start date: December 31, 2019
Phase: Phase 2
Study type: Interventional

The study is a Phase 2, open-label, randomized, 4-arm, parallel group study in subjects with active non-infectious uveitis. Subjects will be randomized to receive either 0.1 mg or 1.0 mg of PL8177 SC injection as 2 single doses 48 hours apart (Group A) or as a single dose for 4 weeks (4 doses) (Group B). A total of 40 subjects are planned to be enrolled with 20 participating in each Group.

NCT ID: NCT04018599 Completed - Clinical trials for Rheumatoid Arthritis

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Start date: July 15, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection of 40 mg.

NCT ID: NCT03711929 Terminated - Clinical trials for Non Infectious Uveitis

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Start date: November 19, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS). There is a 6-month, single-arm, open-label period after completion of the 6-month double- masked, controlled period allows the evaluation of the efficacy and safety of intravitreal injection of DE-109 440 µg every 2 months for longer duration than appropriate for a placebo or sham control.

NCT ID: NCT03634475 Active, not recruiting - Clinical trials for Non-infectious Uveitis

A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis

Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase) and has shown pre-clinical efficacy in treatment of non-infectious uveitis. PP-001 will be administered to participants as a single intravitreal injection in ascending doses.

NCT ID: NCT03308045 Completed - Clinical trials for Non-infectious Uveitis

Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis

Start date: April 4, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Primary objective: safety and tolerability Secondary objectives: additional indicators of long term safety and indicators of clinical activity Exploratory objectives: to characterize EYS606 biodistribution, immunogenicity and biomarkers

NCT ID: NCT02951975 Terminated - Clinical trials for Non-infectious Uveitis

Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye

Louvre 2
Start date: January 25, 2017
Phase:
Study type: Observational

This observational study will evaluate the safety, efficacy, characteristics of patients, characteristics of physicians and quality of life in patients who are prescribed OZURDEX® as treatment for non-infectious uveitis of the posterior segment of the eye in France.

NCT ID: NCT02748512 Completed - Clinical trials for Non-Infectious Uveitis

Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis

MkII
Start date: February 23, 2016
Phase: Phase 3
Study type: Interventional

This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the Mk II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.